22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
17:53 , Jun 11, 2019 |  BC Extra  |  Clinical News

CymaBay down on Phase IIb NASH miss

CymaBay fell $5.04 (45%) to $6.05 on Tuesday after the company announced seladelpar missed the primary endpoint in a Phase IIb trial to treat NASH. In 181 patients with biopsy-confirmed NASH, CymaBay Therapeutics Inc. (NASDAQ:CBAY)...
21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
23:26 , May 14, 2019 |  BC Extra  |  Clinical News

Daiichi gets ODAC split, with FDA panel backing pexidartinib for rare cancer

Missing data and lingering safety questions dogged a pair of Daiichi Sankyo oncology agents that came before ODAC on Tuesday, but a lack of available treatment options for tenosynovial giant cell tumor and a clear...
23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
18:03 , May 2, 2019 |  BC Innovations  |  Translation in Brief

From MSI-high to MSI-higher

A study in Science offers more clues to the consistent but poorly defined link between tumor mutation load and checkpoint inhibitor response. The data could explain why less than half of patients with MSI-high status...
22:22 , Apr 22, 2019 |  BC Innovations  |  Translation in Brief

Oncogenic gene fusions can create neoantigens

Memorial Sloan Kettering Cancer Center researchers have identified gene fusions as a source of cancer neoantigens that could be targeted by immunotherapy. As companies develop immunotherapies against neoantigens, research is increasingly looking beyond point mutations...
19:27 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

CPS1 protein to treat drug-induced liver toxicity

DISEASE CATEGORY: Hepatic INDICATION: Drug-induced liver toxicity (DILI) Mouse studies suggest CPS1 could help treat DILI. In a mouse model of FASL-induced liver toxicity, CPS1 decreased serum levels of alanine transaminase (ALT), a marker of...
02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
20:51 , Mar 6, 2019 |  BC Extra  |  Clinical News

Alnylam's rare liver disease RNAi meets in Phase III

Alnylam’s givosiran met the primary endpoint in the Phase III ENVISION trial to treat acute hepatic porphyria, setting the company up to complete submission of a rolling NDA to FDA and submit an MAA to...